BioNexus Gene Lab (NASDAQ:BGLC) & Vyant Bio (OTCMKTS:VYNT) Financial Review

BioNexus Gene Lab (NASDAQ:BGLC) and Vyant Bio (OTCMKTS:VYNT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Valuation & Earnings

This table compares BioNexus Gene Lab and Vyant Bio’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$9.77 million	1.08	-$2.63 million	($0.02)	-29.68
Vyant Bio	$670,000.00	1.83	-$22.69 million	N/A	N/A

BioNexus Gene Lab has higher revenue and earnings than Vyant Bio.

Profitability

This table compares BioNexus Gene Lab and Vyant Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-26.90%	-32.99%	-26.99%
Vyant Bio	-3,474.81%	-151.82%	-97.14%

Analyst Recommendations

This is a summary of current ratings for BioNexus Gene Lab and Vyant Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	0	0	0	0	N/A
Vyant Bio	0	0	0	0	N/A

Insider and Institutional Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. 6.8% of BioNexus Gene Lab shares are held by company insiders. Comparatively, 9.6% of Vyant Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioNexus Gene Lab beats Vyant Bio on 6 of the 8 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About Vyant Bio

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.